Managing early-stage DLBCL in elderly patients often presents unique clinical challenges for oncologists. However, traditional prognostic tools like the stage-adjusted International Prognostic Index (Sa-IPI) do not always account for comorbidities. Specifically, a recent study from King Hussein Cancer Center analyzed outcomes for patients aged 60 and older. Furthermore, the research team developed a new prognostic tool called the KHCC-EPI. Consequently, they observed that this index significantly improves risk stratification in this population. Moreover, the study found that 5-year survival rates were favorable at 70.4%.

Enhancing Prognostic Index for DLBCL in Elderly Patients

But, a significant portion of deaths in the study resulted from non-lymphoma causes. Therefore, managing underlying health issues is just as important as treating the malignancy itself. In addition, factors such as ECOG performance status and B symptoms predicted poorer outcomes. Because the Charlson Comorbidity Index (CCI) was a strong predictor, the researchers modeled it as a continuous variable. Thus, the KHCC-EPI demonstrated much better discrimination than the standard Sa-IPI. Similarly, this approach aligns with global trends toward integrating geriatric assessment into cancer care. So, clinicians should consider these comorbidities for better treatment optimization. Overall, validating this index externally will be essential for widespread clinical use.

Frequently Asked Questions

What is the KHCC-EPI for DLBCL?

The KHCC-EPI is a simplified prognostic index designed for older adults with early-stage DLBCL. It incorporates performance status, disease stage, B symptoms, and the Charlson Comorbidity Index to provide better risk stratification than the traditional Sa-IPI.

How do comorbidities affect lymphoma outcomes in older patients?

Comorbidities often lead to non-lymphoma-related mortality. Studies show that over half of deaths in older patients with early-stage DLBCL may be unrelated to the cancer, making the management of underlying health conditions critical for survival.

Why is Sa-IPI considered insufficient for some elderly patients?

The Sa-IPI primarily focuses on disease stage and age, but it often ignores the physical vulnerability and multi-morbidity common in seniors. This can lead to inaccurate survival predictions and suboptimal treatment intensity.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ma'koseh M et al. Survival and prognostic features of early-stage diffuse large B-cell lymphoma in older adults. Hematology. 2026 Dec 31. doi: 10.1080/16078454.2026.2653281. PMID: 41922932.

Isaksen KT, Galleberg R, Mastroianni MA. The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy. Haematologica. 2023; 108(9):2454-2466.

Merli F, Luminari S, Tucci A. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the Prospective Elderly Project of the Fondazione Italiana Linfomi. J Clin Oncol. 2021; 39(11):1214-1222.